L
Liwen Xu
Researcher at Stanford University
Publications - 22
Citations - 731
Liwen Xu is an academic researcher from Stanford University. The author has contributed to research in topics: Transplantation & Kinase. The author has an hindex of 9, co-authored 20 publications receiving 638 citations.
Papers
More filters
Journal ArticleDOI
CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation
Kavya Rakhra,Pavan Bachireddy,Tahera Zabuawala,Robert Zeiser,Liwen Xu,Andrew M. Kopelman,Alice C. Fan,Qiwei Yang,Lior Z. Braunstein,Erika J. Crosby,Sandra Ryeom,Dean W. Felsher +11 more
TL;DR: CD4(+) T cells are required for the remodeling of the tumor microenvironment through the expression of chemokines, such as thrombospondins, in order to elicit oncogene addiction.
Journal ArticleDOI
Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens
Alice C. Fan,Debabrita Deb-Basu,Mathias W. Orban,Jason Gotlib,Yasodha Natkunam,Roger A. O'Neill,Rose Ann Padua,Liwen Xu,Daryl Taketa,Amy E. Shirer,Shelly Beer,Ada X Yee,David Voehringer,Dean W. Felsher +13 more
TL;DR: A nanofluidic proteomic immunoassay (NIA) to quantify total and low-abundance protein isoforms in nanoliter volumes for the development of new therapeutics for cancer.
Journal ArticleDOI
High throughput automated chromatin immunoprecipitation as a platform for drug screening and antibody validation
Angela Ruohao Wu,Tiara L.A. Kawahara,Nicole A Rapicavoli,Jan van Riggelen,Emelyn H. Shroff,Liwen Xu,Dean W. Felsher,Howard Y. Chang,Howard Y. Chang,Stephen R. Quake,Stephen R. Quake +10 more
TL;DR: HTChIP is reported, an automated microfluidic-based platform for performing high-throughput ChIP screening measurements of 16 different targets simultaneously, with potential for further scale-up.
Journal ArticleDOI
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Mahesh Seetharam,Alice C. Fan,Mai Tran,Liwen Xu,John P. Renschler,Dean W. Felsher,Kunju Sridhar,Francois Wilhelm,Peter L. Greenberg +8 more
TL;DR: In a Phase I/II clinical trial, higher risk red blood cell-dependent myelodysplastic syndrome patients unresponsive to hypomethylating therapy were treated with the multikinase inhibitor ON 01910, demonstrating encouraging efficacy and drug tolerance.
Journal ArticleDOI
Oligomerization state influences the degradation rate of 3-hydroxy-3-methylglutaryl-CoA reductase.
TL;DR: It is observed that replacement of the cytosolic domain of HMGR with various heterologous proteins can have an effect on the regulated degradation, and the effect correlates with the oligomeric state of the replacement cytOSolic protein.